Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.
March 2, 2026 ·Suzhou China
Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 06938) announced that its PCSK9-targeting siRNA drug RBD7022 / QLC7401, developed in collaboration with Qilu Pharmaceutical Co., Ltd. ("Qilu Pharmaceutical"), has completed the Phase III clinical trial registration (ID: NCT07441317), and is about to initiate the Phase III clinical trial in China by Qilu Pharmaceutical.
RBD7022, independently developed by Ribo using its proprietary siRNA delivery system – RiboGalSTARTM, precisely inhibits the expression of PCSK9 protein in the liver, achieving long-term reduction of low-density lipoprotein cholesterol (LDL-C) level. This technology overcomes the limitation of traditional drugs requiring frequent administration, achieving sustained lipid-lowering effects for several months with single injection, thereby providing a superior therapeutic option for patients with hyperlipidemia. In December 2023, Ribo granted Qilu Pharmaceutical the exclusive rights to develop, manufacture, and commercialize RBD7022 in mainland China, Hong Kong, and Macau.